Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Patritumab deruxtecan by Daiichi Sankyo for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood of Approval
Patritumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Esophageal Squamous Cell Carcinoma (ESCC)....
Patritumab deruxtecan by Daiichi Sankyo for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
Patritumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC)....
Patritumab deruxtecan by Daiichi Sankyo for Epithelial Ovarian Cancer: Likelihood of Approval
Patritumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Epithelial Ovarian Cancer. According to...
Patritumab deruxtecan by Daiichi Sankyo for Peritoneal Cancer: Likelihood of Approval
Patritumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Peritoneal Cancer. According to GlobalData,...
Patritumab deruxtecan by Daiichi Sankyo for Acral Lentiginous Melanoma: Likelihood of Approval
Patritumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Acral Lentiginous Melanoma. According to...
Patritumab deruxtecan by Daiichi Sankyo for Fallopian Tube Cancer: Likelihood of Approval
Patritumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Fallopian Tube Cancer. According to...
Patritumab deruxtecan by Daiichi Sankyo for Endometrial Cancer: Likelihood of Approval
Patritumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Endometrial Cancer. According to GlobalData,...
Patritumab deruxtecan by Daiichi Sankyo for Cervical Cancer: Likelihood of Approval
Patritumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Cervical Cancer. According to GlobalData,...
Valemetostat by Daiichi Sankyo for Peripheral T-Cell Lymphomas (PTCL): Likelihood of Approval
Valemetostat is under clinical development by Daiichi Sankyo and currently in Phase II for Peripheral T-Cell Lymphomas (PTCL). According to...
Ifinatamab deruxtecan by Daiichi Sankyo for Small-Cell Lung Cancer: Likelihood of Approval
Ifinatamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase III for Small-Cell Lung Cancer. According to...
Patritumab deruxtecan by Daiichi Sankyo for Metastatic Breast Cancer: Likelihood of Approval
Patritumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Metastatic Breast Cancer. According to...
Trastuzumab deruxtecan by Daiichi Sankyo for Transitional Cell Cancer (Urothelial Cell Cancer): Likelihood of Approval
Trastuzumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Transitional Cell Cancer (Urothelial Cell...
Valemetostat by Daiichi Sankyo for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
Valemetostat is under clinical development by Daiichi Sankyo and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to...
Valemetostat by Daiichi Sankyo for Small-Cell Lung Cancer: Likelihood of Approval
Valemetostat is under clinical development by Daiichi Sankyo and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData,...
Datopotamab deruxtecan by Daiichi Sankyo for Transitional Cell Cancer (Urothelial Cell Cancer): Likelihood of Approval
Datopotamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Transitional Cell Cancer (Urothelial Cell...
Esaxerenone by Daiichi Sankyo for Diabetic Hypertension: Likelihood of Approval
Esaxerenone is under clinical development by Daiichi Sankyo and currently in Phase II for Diabetic Hypertension. According to GlobalData, Phase...
DS-2325a by Daiichi Sankyo for Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair): Likelihood of Approval
DS-2325a is under clinical development by Daiichi Sankyo and currently in Phase I for Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair)....
Edoxaban tosylate by Daiichi Sankyo for Chronic Thromboembolic Pulmonary Hypertension: Likelihood of Approval
Edoxaban tosylate is under clinical development by Daiichi Sankyo and currently in Phase III for Chronic Thromboembolic Pulmonary Hypertension. According...
Risk adjusted net present value: What is the current valuation of Daiichi Sankyo's Raludotatug Deruxtecan?
Raludotatug Deruxtecan is a monoclonal antibody conjugated commercialized by Daiichi Sankyo, with a leading Phase I program in Renal Cell...
Risk adjusted net present value: What is the current valuation of Daiichi Sankyo's Datopotamab deruxtecan?
Datopotamab deruxtecan is a monoclonal antibody conjugated commercialized by Daiichi Sankyo, with a leading Pre-Registration program in Non-Small Cell Lung...